Eta-1 (osteopontin): An early component of type-1 (cell-mediated) immunity

Science

Volumn 287, Issue 5454, 2000, Pages 860-864

  Ashkar, Samy ^a   Weber, Georg F ^b,c   Panoutsakopoulou, Vassiliki ^b   Sanchirico, Marie E ^b   Jansson, Marianne ^b   Zawaideh, Samer ^a   Rittling, Susan R ^d   Denhardt, David T ^d   Glimcher, Melvin J ^a   Cantor, Harvey ^b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c TUFTS MEDICAL CENTER   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 12; OSTEOPONTIN;

ANIMAL EXPERIMENT; ANTIBODY SPECIFICITY; ARTICLE; AUTOIMMUNITY; CELLULAR IMMUNITY; GENE EXPRESSION REGULATION; IMMUNOREGULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIGENS, CD44; GRANULOMA; HERPES SIMPLEX; HERPESVIRUS 1, HUMAN; HYPERSENSITIVITY, DELAYED; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-12; KERATITIS, HERPETIC; LISTERIA INFECTIONS; LYMPHOCYTE ACTIVATION; MACROPHAGES; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, NUDE; OSTEOPONTIN; PHOSPHORYLATION; RECEPTORS, VITRONECTIN; SIALOGLYCOPROTEINS; T-LYMPHOCYTES;

ANIMALIA; BACTERIA (MICROORGANISMS); HERPES; HUMAN HERPESVIRUS 1; LISTERIA MONOCYTOGENES;

EID: 0034603119     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.287.5454.860     Document Type: Article

References (63)

1. E. R. Uranue, Immunol. Rev. 158, 11 (1997).
2. R. Medzhitov and C. Janeway, Semin. Immunol. 10, 351 (1998).
3. P. Matzinger, Semin. Immunol. 10, 399 (1998).
4. C. M. Scheicher, M. Mehlig, H. P. Dienes, K. Reske, Eur. J. Immunol. 25, 1566 (1995); S. E. Macatonia et al., J. Immunol. 154, 5071 (1995); K. M. Murphy, Curr. Opin. Immunol. 10, 226 (1998).
5. C. M. Scheicher, M. Mehlig, H. P. Dienes, K. Reske, Eur. J. Immunol. 25, 1566 (1995); S. E. Macatonia et al., J. Immunol. 154, 5071 (1995); K. M. Murphy, Curr. Opin. Immunol. 10, 226 (1998).
6. C. M. Scheicher, M. Mehlig, H. P. Dienes, K. Reske, Eur. J. Immunol. 25, 1566 (1995); S. E. Macatonia et al., J. Immunol. 154, 5071 (1995); K. M. Murphy, Curr. Opin. Immunol. 10, 226 (1998).
7. F. Koch et al., J. Exp. Med. 184, 741 (1996).
8. A. O'Garra, Immunity 8, 275 (1998).
9. F. Ria, G. Penna, L. Adorini, Eur. J. Immunol. 28, 2003 (1998).
10. M. D. Sharma, M. L. de Moraes, F. Zavala, C. Pontoux, M. Papiernik, J. Immunol. 161, 5357 (1998).
11. R. Patarca et al., J. Exp. Med. 170, 145 (1989); C. F. Weber, S. Ashkar, H. Cantor, Proc. Assoc. Am. Physicians 109, 1 (1997); S. R. Rittling and D. T. Denhardt, Exp. Nephrol. 7, 103 (1999).
12. R. Patarca et al., J. Exp. Med. 170, 145 (1989); C. F. Weber, S. Ashkar, H. Cantor, Proc. Assoc. Am. Physicians 109, 1 (1997); S. R. Rittling and D. T. Denhardt, Exp. Nephrol. 7, 103 (1999).
13. R. Patarca et al., J. Exp. Med. 170, 145 (1989); C. F. Weber, S. Ashkar, H. Cantor, Proc. Assoc. Am. Physicians 109, 1 (1997); S. R. Rittling and D. T. Denhardt, Exp. Nephrol. 7, 103 (1999).
14. R. P. Singh, R. Patarca, J. Schwartz, P. Singh, H. Cantor, J. Exp. Med. 171, 1931 (1990); X. Q. Yu et al., Proc. Assoc. Am. Physicians 110, 50 (1998); D. T. Denhardt and M. Noda, J. Cell. Biochem. Suppl. 30/31, 92 (1998).
15. R. P. Singh, R. Patarca, J. Schwartz, P. Singh, H. Cantor, J. Exp. Med. 171, 1931 (1990); X. Q. Yu et al., Proc. Assoc. Am. Physicians 110, 50 (1998); D. T. Denhardt and M. Noda, J. Cell. Biochem. Suppl. 30/31, 92 (1998).
16. R. P. Singh, R. Patarca, J. Schwartz, P. Singh, H. Cantor, J. Exp. Med. 171, 1931 (1990); X. Q. Yu et al., Proc. Assoc. Am. Physicians 110, 50 (1998); D. T. Denhardt and M. Noda, J. Cell. Biochem. Suppl. 30/31, 92 (1998).
17. R. Patarca, R. A. Saavedra, H. Cantor, Crit. Rev. Immunol. 13, 225 (1993); T. J. Jerrells and J. V. Osterman, Infect. Immun. 31, 1014 (1981).
18. R. Patarca, R. A. Saavedra, H. Cantor, Crit. Rev. Immunol. 13, 225 (1993); T. J. Jerrells and J. V. Osterman, Infect. Immun. 31, 1014 (1981).
19. G. J. Nau et al., Proc. Natl. Acad. Sci. U.S.A. 94, 6414 (1997); A. W. O'Regan et al., J. Immunol. 162, 1024 (1999).
20. G. J. Nau et al., Proc. Natl. Acad. Sci. U.S.A. 94, 6414 (1997); A. W. O'Regan et al., J. Immunol. 162, 1024 (1999).
21. C. van den Bogert et al., Virchows Arch. 51, 39 (1986).
22. +/+ littermates or age-matched C57BL/6 × 129/SV mice as controls.
23. +/+ mice.
24. L. W. Fisher, J. T. Stubbs, M. F. Young, Acta Orthop. Scand. 66, 61 (1995).
25. Z.-S. Zhao, F. Granucci, L. Yen, P. A. Schaffer, H. Cantor, Science 279, 1344 (1998); A. C. Avery et al., Nature 376, 431 (1995).
26. Z.-S. Zhao, F. Granucci, L. Yen, P. A. Schaffer, H. Cantor, Science 279, 1344 (1998); A. C. Avery et al., Nature 376, 431 (1995).
27. J. W. Streilein, M. R. Dana, B. R. Ksander, Immunol. Today 18, 443 (1997); M. Daheshia, N. Kuklin, S. Kanangat, E. Manickan, B. T. Rouse, J. Immunol. 159, 1945 (1997).
28. J. W. Streilein, M. R. Dana, B. R. Ksander, Immunol. Today 18, 443 (1997); M. Daheshia, N. Kuklin, S. Kanangat, E. Manickan, B. T. Rouse, J. Immunol. 159, 1945 (1997).
29. 7 PFU of ultraviolet (UV)-inactivated HSV-1 (KOS). Supernatants harvested 48 hours later were tested for IL-10 and IL-12 p40 cytokine by sandwich enzyme-linked immunosorbent assay (ELISA) using OptEIA antibody sets (PharMingen, La Jolla, CA). IL-4 was measured after stimulation of draining lymph node cells by plate-bound antibody to CD3.
30. S. Ashkar et al., data not shown.
31. A. Oxenius, U. Karrer, R. M. Zinkernagel, H. Hengartner, J. Immunol. 162, 965 (1999); L. P. Cousens et al., J. Exp. Med. 189, 1315 (1999).
32. A. Oxenius, U. Karrer, R. M. Zinkernagel, H. Hengartner, J. Immunol. 162, 965 (1999); L. P. Cousens et al., J. Exp. Med. 189, 1315 (1999).
33. C. S. Tripp, S. F. Wolf, E. R. Unanue, Proc. Natl. Acad. Sci. U.S.A. 90, 3725 (1993); C. S. Tripp, M. K. Gately, J. Hakimi, P. Ling, E. R. Unanue, J. Immunol. 152, 1883 (1994); C. S. Tripp, O. Kanagawa, E. R. Unanue, J. Immunol. 155, 3427 (1995).
34. C. S. Tripp, S. F. Wolf, E. R. Unanue, Proc. Natl. Acad. Sci. U.S.A. 90, 3725 (1993); C. S. Tripp, M. K. Gately, J. Hakimi, P. Ling, E. R. Unanue, J. Immunol. 152, 1883 (1994); C. S. Tripp, O. Kanagawa, E. R. Unanue, J. Immunol. 155, 3427 (1995).
35. C. S. Tripp, S. F. Wolf, E. R. Unanue, Proc. Natl. Acad. Sci. U.S.A. 90, 3725 (1993); C. S. Tripp, M. K. Gately, J. Hakimi, P. Ling, E. R. Unanue, J. Immunol. 152, 1883 (1994); C. S. Tripp, O. Kanagawa, E. R. Unanue, J. Immunol. 155, 3427 (1995).
36. -/- mice contained liver-associated Listeria-infected cysts that were apparent 4 to 5 days after infection. Plates were incubated at 37°C, and the numbers of CFU were counted after 24 hours.
37. 8 CFU/ml) 96 hours before IFN-γ measurement by an OptEIA ELISA kit (PharMingen).
38. P. Stordeur et al., Mol. Immunol. 32, 233 (1995); P. Stordeur and M. Goldman, Int. Rev Immunol. 16, 501 (1998).
39. P. Stordeur et al., Mol. Immunol. 32, 233 (1995); P. Stordeur and M. Goldman, Int. Rev Immunol. 16, 501 (1998).
40. C. F. Weber, S. Ashkar, M. J. Glimcher, H. Cantor, Science 271, 509 (1996).
41. L. Liaw et al., J. Clin. Invest. 95, 713 (1995); D. R. Senger et al., Am. J. Pathol. 149, 293 (1996).
42. L. Liaw et al., J. Clin. Invest. 95, 713 (1995); D. R. Senger et al., Am. J. Pathol. 149, 293 (1996).
43. Addition of 5 mM GRGDS peptide but not GRADS peptide (29) to cultures of peritoneal macrophages (38) resulted in an 80% reduction of the IL-12 response after LPS stimulation.
44. Single-letter abbreviations for the amino acid residues are as follows: A, Ala; D, Asp; E, Glu; G, Gly; L, Leu; N, Asn; P, Pro; Q, Gln; R, Arg; S, Ser; and T, Thr.
45. R. Schmits et al., Blood 90, 2217 (1997).
46. T. Kubota et al., Biochem. Biophys. Res. Commun. 162, 1453 (1989); A. F. Chambers, E. I. Behrend, S. M. Wilson, D. T. Denhardt, Anticancer Res. 12, 43 (1992); E. S. Sorensen and T. E. Petersen, Biochem. Biophys. Res. Commun. 198, 200 (1994); H. Salih, S. Ashkar, L C. Gerstenfeld, M. J. Glimcher, J. Biol. Chem. 272, 13966 (1997).
47. T. Kubota et al., Biochem. Biophys. Res. Commun. 162, 1453 (1989); A. F. Chambers, E. I. Behrend, S. M. Wilson, D. T. Denhardt, Anticancer Res. 12, 43 (1992); E. S. Sorensen and T. E. Petersen, Biochem. Biophys. Res. Commun. 198, 200 (1994); H. Salih, S. Ashkar, L C. Gerstenfeld, M. J. Glimcher, J. Biol. Chem. 272, 13966 (1997).
48. T. Kubota et al., Biochem. Biophys. Res. Commun. 162, 1453 (1989); A. F. Chambers, E. I. Behrend, S. M. Wilson, D. T. Denhardt, Anticancer Res. 12, 43 (1992); E. S. Sorensen and T. E. Petersen, Biochem. Biophys. Res. Commun. 198, 200 (1994); H. Salih, S. Ashkar, L C. Gerstenfeld, M. J. Glimcher, J. Biol. Chem. 272, 13966 (1997).
49. T. Kubota et al., Biochem. Biophys. Res. Commun. 162, 1453 (1989); A. F. Chambers, E. I. Behrend, S. M. Wilson, D. T. Denhardt, Anticancer Res. 12, 43 (1992); E. S. Sorensen and T. E. Petersen, Biochem. Biophys. Res. Commun. 198, 200 (1994); H. Salih, S. Ashkar, L C. Gerstenfeld, M. J. Glimcher, J. Biol. Chem. 272, 13966 (1997).
50. M. Nemir, M. W. DeVouge, B. B. Mukherjee, J. Biol. Chem. 264, 18202 (1989); B. Ek-Rylander, M. Flores, M. Wendel, D. Heinegard, C. Andersson, J. Biol. Chem. 269, 14853 (1994).
51. M. Nemir, M. W. DeVouge, B. B. Mukherjee, J. Biol. Chem. 264, 18202 (1989); B. Ek-Rylander, M. Flores, M. Wendel, D. Heinegard, C. Andersson, J. Biol. Chem. 269, 14853 (1994).
52. Dephosphorylation of Eta-1 is as follows. Five milligrams of purified Eta-1 was dephosphorylated using 6 U (60 U/mg) of type-II potato acid phosphatase (Sigma) as described (39). Phosphorylation of recombinant Eta-1:glutathione S-transferase (GST)-Eta-1 (5 mg) was phosphorylated as described [S. Ashkar, J. L. Schaffer, E. Salih, L. C. Gerstenfeld, M. J. Glimcher, Ann. N.Y. Acad. Sci. 760, 296 (1995); (27)]. Phosphoamino acid analysis of the recovered protein revealed a phosphoserine content of 16 mol of phosphate per 1 mol of protein and 0.8 mol of phosphothreonine per 1 mol of protein.
53. S. L. Constant and K. Bottomly, Annu. Rev. Immunol. 15, 297 (1999).
54. B. M. Segal, B. K. Dwyer, E. M. Shevach, J. Exp. Med. 187, 537 (1998).
55. A. Lyons, J. L. Kelly, M. L. Rodrick, J. A. Mannick, J. A. Lederer, Ann. Surg. 226, 450 (1997); J. L. Kelly, A. Lyons, C. C. Soberg, J. A. Mannick, J. A. Lederer, Surgery 122, 146 (1997).
56. A. Lyons, J. L. Kelly, M. L. Rodrick, J. A. Mannick, J. A. Lederer, Ann. Surg. 226, 450 (1997); J. L. Kelly, A. Lyons, C. C. Soberg, J. A. Mannick, J. A. Lederer, Surgery 122, 146 (1997).
57. Z. Yin et al., Arthritis Rheum. 40, 1788 (1997).
58. -/- mice were coinjected with this inoculum of PVP and 10 μg of Eta-1 and purified as described below. After 5 days, mice were killed, tissue was extracted for histologic analysis, and local lymph nodes were obtained for cytokine expression. Samples were fixed in 10% buffered formalin and embedded in paraffin; 4- to 5-μm serial sections were stained with hematoxylin and eosin, and images were captured with a Sony DXC-970MD video camera and Optima 5.2 Histomorphometric analysis software.
59. S. Ashkar et al., Biochem. Biophys. Res. Comm. 191, 126 (1993).
60. 2-terminal and internal peptide analysis). Mass spectroscopic analysis revealed a peak centered around a mass of 35,400 daltons that was highly phosphorylated (11 mol of phosphate per 1 mol of protein), O-glycosylated but not N-glycosylated, and without measurable sulfate.
61. 3 was from PharMingen [J. F. Schultz and D. R. Armant, J. Biol. Chem. 270, 11522 (1995)], and antibody to CD44, KM81 (ATCC), was used to block the interaction between CD44 and Eta-1 (16).
62. 2-terminal sequence QETLPSN (29)] was active and predicted to terminate at the thrombin cleavage site. This 10-kD fragment contained ∼5 mol of phosphate per 1 mol of peptide at seven potential phosphorylation sites.
63. -/- mice; B. J. Rollins for L. monocytogenes strain 1778; S. Hikita and D. Block for technical assistance; and A. Angel, K. MacKay, and L. Lagasse for assistance in the preparation of the manuscript.